newsfilter
← Earnings
Earnings Releases·

IDEAYA Biosciences — Third Quarter 2026 Earnings Summary

  • Collaboration revenue rose to $10.2 million from $8.9 million in the prior quarter, while R&D and G&A expenses increased to $121.6 million and $26.3 million respectively, resulting in a net loss of $125.7 million compared to $112.5 million previously; cash and marketable securities decreased to $1.15 billion from $1.24 billion.
  • The company submitted an NDA for darovasertib plus crizotinib in metastatic uveal melanoma and halted the Phase 3 OptimUM-010 trial due to enrollment challenges, a move expected to save $100-125 million to be reallocated to programs including IDE849 and IDE892.
  • Future outlook includes initiating two Phase 3 registrational trials for IDE849 in ES-SCLC and NEC by end of 2026, with initial data for IDE849 expected by late 2026 or early 2027, and a Phase 1 trial for IDE892 in combination with RG6505 targeted for initiation by year-end.
  • Cash runway guidance into 2030 remains unchanged, and management announced the promotion of Dr. Michael White to President, Research and Development, alongside new clinical collaborations with Roche and Genentech targeting KRAS-mutant cancers.
Company
IDEAYA BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology